Entera Bio Ltd. (ENTX) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 67% of 52W Range • RSI-14 at 63.6 (BULLISH MOMENTUM)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ENTX currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.90) and Max Pain ($3.28) forces dealer call-delta covering toward $4.41.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Entera Bio Ltd. (ENTX) advanced +0.65% to $3.12, trading at 67% of its 52-week range ($0.91 – $4.2). Stretched risk/reward at current multiples (-34% return on capital) under elevated 10-year interest-rate pressure.
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity Therapeutics
Civeo shares surged 19.9% after earnings beat estimates and FY2026 sales guidance rose; other premarket movers included SLGB, HUBC and ATEC.
Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN) He joins Entera with two decades of clinical development, regulatory execution, and women’s
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced the appointment of Geno Germano to its Board of Direct
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ENTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ENTX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Entera Bio Ltd. (ENTX) ranks #636 by composite RQD confidence (40/100, grade D-) and #433 by equity capitalization ($542.6M). Within this direct 5-issuer industry benchmark cohort, ENTX leads on earnings valuation at N/A trailing P/E, while ENTX leads on capital efficiency and profitability with -33.6% ROIC and 0.0% gross margin. VALN currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with ENTX at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ENTX
ACTIVE
Entera Bio Ltd. | D- | 40/100 | — | 0.0% | -33.6% | +0.65% | $542.6M | Benchmark Subject |
| ETRA Electra Therapeutics Inc. | D | 48/100 | — | — | — | -3.79% | $542.3M | /etra-vs-entx → |
| VALN Valneva SE | D+ | 58/100 | — | — | — | -0.52% | $541.8M | /valn-vs-entx → |
| SRZN Surrozen Inc. | E | 27/100 | — | — | -35.0% | -2.93% | $524.4M | /srzn-vs-entx → |
| RGNX REGENXBIO Inc. | D- | 39/100 | — | — | -35.0% | +2.35% | $489.2M | /rgnx-vs-entx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Entera Bio Ltd. (ENTX) reported GAAP revenue of $42.0K (-76.8% vs. FY2024 revenue of $181.0K ) , GAAP net income of -$11.4M, operating cash flow of -$7.4M, and free cash flow of -$7.5M (-9.6% YoY). On the balance sheet, ENTX closed FY2025 with $16.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $42.0K | -$11.4M | -$7.4M | -$7.5M | $16.0M | — |
| FY2024 (FY) | 2024-12-31 | $181.0K | -$9.5M | -$6.8M | -$6.8M | $9.4M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$8.9M | -$7.3M | -$7.3M | — | — |
As of 2026-11-01, Entera Bio Ltd. (NASDAQ: ENTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $3.12 (+0.65% 1D, market cap $542.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ENTX ranks #636 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ENTX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 0.0%, and ROIC of -33.6%. By comparison, ETRA (Electra Therapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $542.3M) and VALN (Valneva SE) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $541.8M). Among the 5-stock peer group, ENTX leads on earnings multiple (N/A) while ENTX leads on capital efficiency (-33.6% ROIC).
Per ENTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001638097), Entera Bio Ltd. generated $42.0K in revenue (-76.8% YoY), -$11.4M in net income, and -$7.5M in free cash flow against $16.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ENTX last traded at $3.12 (+0.65% on volume of 140,956 shares), positioning the stock +7.59% above its 50-day simple moving average ($2.90) and +63.35% above its 200-day simple moving average ($1.91). Across its 52-week range of $0.91 to $4.20, ENTX sits at the 67.2% percentile with a 14-day RSI of 63.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.73 to $3.51).
Why ENTX Stock advanced +0.65% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-34% return on capital) under elevated 10-year interest-rate pressure.